Latest Commercial Agreements News

EQ Resources has refinanced €15 million of debt for its Spanish subsidiary through a three-year prepayment facility and locked in a five-year tungsten sales agreement valued at A$678 million.

Spacetalk Ltd has signed a non-binding MOU with Vodafone Australia to distribute its Family Safety software platform, marking a strategic shift towards a software-led business model and aiming for significant recurring revenue growth.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Cyclopharm Limited is rapidly scaling its US presence for Technegas®, securing new contracts across federal institutions and major health networks in four key regions. The company aims for up to 300 installations by late 2026, boosting recurring revenue streams.

Euro Manganese Inc. reported a net loss of $3.6 million for Q3 2025 and extended key financing milestones to June 2026, highlighting ongoing challenges in funding its Chvaletice Manganese Project.

SportsHero Limited has raised $4.3 million through a private placement, including a significant commitment from its CEO, to accelerate its HeroPlay rollout across Southeast Asia.

Meteoric Resources has successfully commissioned its Mixed Rare Earth Carbonate pilot plant in Brazil, achieving strong recovery rates and production outputs that validate its processing approach and de-risk the Caldeira project.

Klevo Rewards Limited’s subsidiary Fly Wallet has secured key Mastercard compliance and earned over AUD 550,000 in incentives, marking a significant step in its payments platform evolution.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.